{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:32:49Z","timestamp":1787758369337,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Tofacitinib has been reported to activity in the recovery of alopecia areata (AA) in several reports, mainly from Western countries. We report the case of a young Indian boy with resistant AA who was treated with tofacitinib-based therapy. Improvements in terms of hair regrowth were observed within 6\u20138 weeks of treatment with oral tofacitinib 2.5 mg BID tablets, and the hair regrowth was nearly complete by 5 months. There were no associated side effects and the treatment with tofacitinib was well-tolerated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijt.ijt_15_22","type":"journal-article","created":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T23:58:30Z","timestamp":1661471910000},"page":"135-137","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Recovery of Resistant Alopecia Areata Treated with Tofacitinib"],"prefix":"10.4103","volume":"14","author":[{"given":"Anil","family":"Bhokare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20240903","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/pde.14422","article-title":"Treatment of alopecia areata in pre-adolescent children with oral tofacitinib: A retrospective study","volume":"38","author":"Jerjen","year":"2021","journal-title":"Pediatr Dermatol"},{"key":"R2-5-20240903","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jaad.2018.12.041","article-title":"Tofacitinib therapy for children with severe alopecia areata","volume":"80","author":"Dai","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R3-5-20240903","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1525-1470.2006.00161.x","article-title":"The epidemiology of childhood alopecia areata in China: A study of 226 patients","volume":"23","author":"Xiao","year":"2006","journal-title":"Pediatr Dermatol"},{"key":"R4-5-20240903","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jisp.2020.04.005","article-title":"JAK inhibitors for the treatment of pediatric alopecia areata","volume":"20","author":"Hamilton","year":"2020","journal-title":"J Investig Dermatol Symp Proc"},{"key":"R5-5-20240903","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","article-title":"Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R6-5-20240903","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R7-5-20240903","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1001\/jamadermatol.2017.0001","article-title":"Treatment of alopecia areata with tofacitinib","volume":"153","author":"Ibrahim","year":"2017","journal-title":"JAMA Dermatol"},{"key":"R8-5-20240903","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R9-5-20240903","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/j.jaad.2018.02.031","article-title":"Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis","volume":"78","author":"Putterman","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R10-5-20240903","first-page":"914","article-title":"An excellent response to tofacitinib in a pediatric alopecia patient: A case report and review","volume":"17","author":"Brown","year":"2018","journal-title":"J Drugs Dermatol"}],"container-title":["International Journal of Trichology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_15_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:11:23Z","timestamp":1787757083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_15_22"}},"subtitle":["An 8-Year-Old Child's Case Report"],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijt.ijt_15_22","relation":{},"ISSN":["0974-7753"],"issn-type":[{"value":"0974-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}